· drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by...

8

Transcript of  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by...

Page 1:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 2:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 3:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 4:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 5:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 6:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 7:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer
Page 8:  · drug majors Cipla, Ranbaxy Lab, Hetero Drugs, Natco Pharma and others on an appeal filed by Swiss firm Novartis, challenging the denial of Patent for Glivec, its blood cancer

Roche v natco

Roche v natco

NATCO PHARMA LIMITED

NATCO PHARMA LIMITED

Ranbaxy daiichi

Ranbaxy daiichi

Ranbaxy Complaint

Ranbaxy Complaint

ranbaxy proj

ranbaxy proj

NATCO Moderator Orientation

NATCO Moderator Orientation

Product Information for Glivec - Therapeutic Goods ... · Web viewAttachment 1: Product information for AusPAR Glivec Novartis Pharmaceuticals Australia Pty Ltd PM-2011-02797-3-4

Product Information for Glivec - Therapeutic Goods ... · Web viewAttachment 1: Product information for AusPAR Glivec Novartis Pharmaceuticals Australia Pty Ltd PM-2011-02797-3-4

Ranbaxy Acquisition

Ranbaxy Acquisition

Main Ranbaxy

Main Ranbaxy

Ranbaxy 09

Ranbaxy 09

6651555-Scomi Natco - Ndt

6651555-Scomi Natco - Ndt

ppt ranbaxy

ppt ranbaxy

Natco HUST

Natco HUST

Ranbaxy Ltd.

Ranbaxy Ltd.

Natco presentation 1.3

Natco presentation 1.3

Disturbances of Growth Control- · bind Pro-rich regions ... 2012-2020 GIST patient w abdominal mets before Glivec treatment 48 hr after Glivec 8 days after Glivec Positron Emission

Disturbances of Growth Control- · bind Pro-rich regions ... 2012-2020 GIST patient w abdominal mets before Glivec treatment 48 hr after Glivec 8 days after Glivec Positron Emission

NATCO Pharma LimitedNATCO Pharma Inc. Time Cap Overseas Limited NATCO Pharma (Canada), Inc. NATCO Pharma Asia Pte. Ltd. NATCO Pharma Australia PTY Ltd. NATCO Farma Do Brasil L TDA

NATCO Pharma LimitedNATCO Pharma Inc. Time Cap Overseas Limited NATCO Pharma (Canada), Inc. NATCO Pharma Asia Pte. Ltd. NATCO Pharma Australia PTY Ltd. NATCO Farma Do Brasil L TDA

Ranbaxy laboratories

Ranbaxy laboratories

Project Ranbaxy

Project Ranbaxy

Glivec - European Medicines Agency · i.e. 50 mg and 100 mg hard capsules, and 100 mg and 400 mg film coated tablets, respectively, ... acetaminophen/ paracetamol and Glivec/Glivec

Glivec - European Medicines Agency · i.e. 50 mg and 100 mg hard capsules, and 100 mg and 400 mg film coated tablets, respectively, ... acetaminophen/ paracetamol and Glivec/Glivec